United States · Platforms & data · Morningstar

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

Published by Morningstar · United States 8 h ago

Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026 and following the completion of customary…

Read the full article on Morningstar Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.morningstar.com)

Also worth reading

The Motley Fool

Oracle Calls Force Majeure Already?

MarketWatch

Bull markets tend to peak with a whimper, not a bang — but a 15% correction for the S&P 500 may be next

MarketBeat

vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia

Seeking Alpha

Oil prices end lower in volatile session amid reports of U.S.-Iran diplomacy

Investing.com

NextDC shares plunge 42% to a near nine-year low after outlook cut

Yahoo Finance